Dogwood Therapeutics Stock Price, News & Analysis

Dogwood Therapeutics (DWTX) reported Q1 2025 financial results and key developments. The company has begun dosing patients in its Halneuron® Phase 2b study for Chemotherapy Induced Neuropathic Pain (CINP), with interim data expected in Q4 2025. The company's financial position includes $17.5M cash on hand, providing runway through Q1 2026, bolstered by a $4.8M stock raise and conversion of a $19.5M loan to equity by CK Life Sciences. Q1 2025 saw increased R&D expenses of $2.4M (up from $0.3M in Q1 2024) and G&A expenses of $2.0M (up from $1.0M). The net loss was $12.2M or $8.45 per share. The company regained Nasdaq compliance and maintains FDA fast track designation for Halneuron® in CINP treatment.

Dogwood Therapeutics (NASDAQ: DWTX) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. CEO and Chairman Greg Duncan will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Those interested in scheduling meetings can contact John Perez at jperez@dboralcapital.com for registration.

Dogwood Therapeutics (DWTX) has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, following a notification of non-compliance received on November 15, 2024. The company submitted a compliance plan on December 27, 2024, and was granted until May 14, 2025, to meet the requirement.

The biopharmaceutical company, focused on developing medicines for pain and fatigue-related disorders, reports a strong cash position of $17.5 million as of Q1. DWTX is currently conducting a Phase 2b trial for Halneuron® in Chemotherapy Induced Neuropathic Pain, with interim data analysis planned for Q4 2025.

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced it believes it has regained compliance with Nasdaq's minimum stockholders’ equity requirement, as per Listing Rule 5550(b)(1). The company, focused on developing medicines for pain and fatigue-related disorders, has a strong cash position of $17.5 million with no debt as of Q1 end. On November 15, 2024, DWTX was notified it fell below the $2.5 million minimum equity requirement. A compliance plan was submitted on December 27, 2024, and Nasdaq granted an extension until May 14, 2025. Key transactions include a Debt Exchange and Cancellation Agreement with Conjoint, Inc., converting $19.9 million in debt to Series A-1 Non-Voting Convertible Preferred Stock, and a stock purchase agreement raising $4.8 million from institutional investors. As of March 31, 2025, DWTX had 1,911,128 shares of common stock outstanding.

Dogwood Therapeutics (NASDAQ: DWTX) has reported its Q4 and full-year 2024 financial results, highlighting significant developments in its pipeline. The company has begun dosing patients in the Halneuron® Phase 2b trial for Chemotherapy Induced Neuropathic Pain (CINP), with interim data expected in Q4 2025.

Financial highlights include a $19.5M debt-to-equity conversion by major shareholder CK Life Sciences, and a $4.8M common stock raise, extending operational runway through Q1 2026. The company reported a Q4 2024 net loss of $8.2M ($6.29 per share) compared to $1.1M in Q4 2023. Full-year 2024 net loss was $12.9M ($12.52 per share).

R&D expenses increased to $2.3M in Q4 2024 from $0.3M in Q4 2023, while G&A expenses rose to $5.2M from $0.8M. Cash position stands at $14.8M as of December 31, 2024.

Dogwood Therapeutics (NASDAQ: DWTX) has initiated dosing in its Phase 2b clinical trial (HALT-CINP) evaluating Halneuron® for chemotherapy-induced neuropathic pain (CINP). The drug targets the NaV 1.7 sodium channel and represents a potential opioid-free, addiction-free treatment for the $1.5B worldwide CINP market.

Halneuron® has demonstrated promising results in previous trials, showing statistically significant reduction in cancer-related pain with an acceptable safety profile. The drug has been tested in over 700 patients across Phase 1 and 2 studies, showing no addiction potential.

The company aims to recruit 100 CINP patients by Q4 2025, with an interim analysis planned for the same quarter. The adaptive trial design allows for potential study modifications to optimize outcomes.

Dogwood Therapeutics (NASDAQ: DWTX) has announced a registered direct offering of 578,950 shares of common stock priced at $8.26 per share, aiming to raise approximately $4.8 million in gross proceeds. The offering, priced at-the-market under Nasdaq rules, is expected to close on March 14, 2025.

The proceeds will be used to advance the clinical development of Halneuron®, the company's lead candidate for non-opioid pain treatment, and for working capital purposes. Combined with existing cash, this financing will fund operations through Q1 2026. The company plans to announce interim data from its ongoing Halneuron® Phase 2b trial in chemotherapy-induced neuropathic pain (CINP) in Q4 2025.

Maxim Group is serving as the sole placement agent for the offering, which is being conducted under an effective shelf registration statement previously filed with the SEC.

Dogwood Therapeutics (Nasdaq: DWTX) announces the conversion of $19.5 million in debt to equity, as its largest shareholder CK Life Sciences Int'l converts outstanding loan amounts into 284.2638 shares of preferred equity. This strategic move eliminates all existing debt from Dogwood's balance sheet.

The conversion demonstrates CKLS's confidence in Halneuron®, a first-in-class NaV 1.7 specific voltage gated sodium channel inhibitor being developed for chronic and acute pain treatment. The financing, initially provided in October 2024, ensures capital for patient recruitment through a planned interim assessment of the ongoing Phase 2b CINP (chemotherapy-induced neuropathic pain) trial in Q4 2025.

Each preferred share will be convertible into 10,000 common shares, subject to stockholder and Nasdaq approval. Notably, Halneuron® has shown promising results in previous trials, demonstrating significant reduction in cancer-related pain across 700+ patients with no addiction potential.

Dogwood Therapeutics (NASDAQ: DWTX) announced plans to begin patient dosing in Q1 2025 for its Phase 2b clinical trial (HALT-CINP) evaluating Halneuron®, a first-in-class Nav 1.7 inhibitor for treating chemotherapy-induced neuropathic pain (CINP). The drug has shown promising results in previous trials, demonstrating statistically significant reduction in cancer-related pain with an acceptable safety profile across over 700 patients, and importantly, shows no addiction potential.

The company is targeting a significant unmet medical need, as one-third of patients treated with certain chemotherapeutics develop chronic painful neuropathy, with no currently approved treatments. The CINP market is valued at approximately $1.5B, representing a substantial opportunity for Dogwood Therapeutics.